Literature DB >> 3002662

Inotropic effects of amrinone and milrinone on contraction and relaxation of isolated cardiac muscle.

S U Sys, M J Goenen, C H Chalant, D L Brutsaert.   

Abstract

The inotropic response to amrinone and milrinone in isolated cat papillary muscle is characterized by a dose-dependent increase in contractility, with milrinone about five times as potent as amrinone, no effect on load dependence of relaxation, no change in timing and duration of the contraction-relaxation cycle, and marked temperature dependence. This response necessitates, at least in part, the presence of a well-functioning sarcoplasmic reticulum (SR). Amrinone and milrinone are less active when the SR is poorly developed, as in frog myocardium, mammalian atrial myocardium, Purkinje fibers, and ventricular muscle from fetal and newborn animals; when the SR has been destroyed, as in single mammalian cardiac cells; and when the SR, for reasons still under investigation, has become inactive, as in isolated human ventricular myocardium. Amrinone and milrinone are also less active or may depress contractility under conditions in which the SR is known to function near maximal calcium saturation (as in rat ventricular myocardium) or to be overloaded with calcium (as during reoxygenation). This depressant action suggests concomitant desensitization of the contractile proteins to calcium.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3002662

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Involvement of purine compounds in the inotropic action of milrinone.

Authors:  P Dorigo; R M Gaion; I Maragno
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

2.  Incidence of milrinone blood levels outside the therapeutic range and their relevance in children after cardiac surgery for congenital heart disease.

Authors:  Gonzalo Garcia Guerra; Ari R Joffe; Ambikaipakan Senthilselvan; Demetrios J Kutsogiannis; Christopher S Parshuram
Journal:  Intensive Care Med       Date:  2013-02-22       Impact factor: 17.440

Review 3.  Controversies in the identification and management of acute pulmonary hypertension in preterm neonates.

Authors:  Regan E Giesinger; Kiran More; Jodie Odame; Amish Jain; Robert P Jankov; Patrick J McNamara
Journal:  Pediatr Res       Date:  2017-10-04       Impact factor: 3.756

Review 4.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 5.  Care of the critically ill neonate with hypoxemic respiratory failure and acute pulmonary hypertension: framework for practice based on consensus opinion of neonatal hemodynamics working group.

Authors:  Amish Jain; Regan E Giesinger; Shyamala Dakshinamurti; Yasser ElSayed; Robert P Jankov; Dany E Weisz; Satyan Lakshminrusimha; Souvik Mitra; Mjaye L Mazwi; Joseph Ting; Michael Narvey; Patrick J McNamara
Journal:  J Perinatol       Date:  2022-01-11       Impact factor: 3.225

Review 6.  Phosphodiesterase III inhibitors: long-term risks and short-term benefits.

Authors:  J M Cruickshank
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.